WAY-470 is a drug which acts as an agonist at 5-HT2A and 5-HT2C receptors though with lower affinity at 5-HT2B. It has similar binding affinity to 5-HT2A and 5-HT2C but shows functional selectivity for 5-HT2C.[1][2]

WAY-470
Identifiers
  • 1,16-diazatetracyclo[8.8.1.02,9.014,19]nonadeca-2(9),10,12,14(19)-tetraene
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC17H22N2
Molar mass254.377 g·mol−1
3D model (JSmol)
  • C1CCCC2=C(CC1)C3=CC=CC4=C3N2CCNC4
  • InChI=1S/C17H22N2/c1-2-4-9-16-14(7-3-1)15-8-5-6-13-12-18-10-11-19(16)17(13)15/h5-6,8,18H,1-4,7,9-12H2
  • Key:FEOKYCHGJRHIDE-UHFFFAOYSA-N

See also

edit

References

edit
  1. ^ Sabb AL, Vogel RL, Welmaker GS, Sabalski JE, Coupet J, Dunlop J, et al. (May 2004). "Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor". Bioorganic & Medicinal Chemistry Letters. 14 (10): 2603–2607. doi:10.1016/j.bmcl.2004.02.100. PMID 15109661.
  2. ^ Lee J, Jung ME, Lee J (November 2010). "5-HT2C receptor modulators: a patent survey". Expert Opinion on Therapeutic Patents. 20 (11): 1429–1455. doi:10.1517/13543776.2010.518956. PMID 20849206. S2CID 32729624.